Liquidia Corporation announced preliminary, unaudited net product sales of approximately $90.1 million for YUTREPIA™ (treprostinil) inhalation powder in the fourth quarter of 2025 and $148.3 million for the full year 2025. Since its commercial launch in June 2025, YUTREPIA has received more than 2,800 unique patient prescriptions. The company reported generating more than $30 million in positive cash flow during the fourth quarter of 2025. These results reflect the commercial launch of YUTREPIA for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) patient populations. Liquidia plans to report fully audited financial results for the year ended December 31, 2025, in February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622765-en) on January 09, 2026, and is solely responsible for the information contained therein.